{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:51:48Z","timestamp":1791564708543,"version":"4.3.4"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"DOI":"10.1038\/s41585-026-01189-w","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:01:36Z","timestamp":1791561696000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cribriform and intraductal carcinoma in prostate cancer \u2014 implications for risk stratification and therapeutic decision-making"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8076-4550","authenticated-orcid":false,"given":"Rui M.","family":"Bernardino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-1391","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyad","family":"Schwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8640-5786","authenticated-orcid":false,"given":"Theodorus","family":"van der Kwast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam B.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane K.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1962-7968","authenticated-orcid":false,"given":"Estev\u00e3o","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Soputro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashed","family":"Ghandour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6742-0040","authenticated-orcid":false,"given":"Alp Tuna","family":"Beksac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Daher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Le\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark L.","family":"Gonzalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick","family":"van den Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Garisto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Le Gu\u00e9velou Kammerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1559-7754","authenticated-orcid":false,"given":"Sara M.","family":"Falzarano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1219-3797","authenticated-orcid":false,"given":"Cristina","family":"Magi-Galuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2190-512X","authenticated-orcid":false,"given":"Cosimo","family":"De Nunzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Prendeville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Fleshner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7127-6069","authenticated-orcid":false,"given":"Jihad","family":"Kaouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7045-7725","authenticated-orcid":false,"given":"Riccardo","family":"Autorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"1189_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/J.EURURO.2015.06.046","volume":"69","author":"JI Epstein","year":"2016","unstructured":"Epstein, J. I. et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur. Urol. 69, 428\u2013435 https:\/\/doi.org\/10.1016\/J.EURURO.2015.06.046 (2016).","journal-title":"Eur. Urol."},{"key":"1189_CR2","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00428-022-03301-y","volume":"480","author":"N Seyrek","year":"2022","unstructured":"Seyrek, N. et al. Alternative prostate cancer grading systems incorporating percent pattern 4\/5 (IQ-Gleason) and cribriform architecture (cGrade) improve prediction of outcome after radical prostatectomy. Virchows Arch. 480, 1149\u20131157 https:\/\/doi.org\/10.1007\/s00428-022-03301-y (2022).","journal-title":"Virchows Arch."},{"key":"1189_CR3","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.ejso.2020.12.014","volume":"47","author":"K Mori","year":"2021","unstructured":"Mori, K. et al. Differential prognostic impact of different Gleason patterns in grade group 4 in radical prostatectomy specimens. Eur. J. Surg. Oncol. 47, 1172\u20131178 https:\/\/doi.org\/10.1016\/j.ejso.2020.12.014 (2021).","journal-title":"Eur. J. Surg. Oncol."},{"key":"1189_CR4","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.pathol.2024.12.633","volume":"57","author":"L Egevad","year":"2025","unstructured":"Egevad, L. et al. Gleason scores provide more accurate prognostic information than grade groups. Pathology 57, 293\u2013296 https:\/\/doi.org\/10.1016\/j.pathol.2024.12.633 (2025).","journal-title":"Pathology"},{"key":"1189_CR5","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/MODPATHOL.2016.49","volume":"29","author":"CF Kweldam","year":"2016","unstructured":"Kweldam, C. F. et al. Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy. Mod. Pathol. 29, 630\u2013636 https:\/\/doi.org\/10.1038\/MODPATHOL.2016.49 (2016).","journal-title":"Mod. Pathol."},{"key":"1189_CR6","doi-asserted-by":"publisher","first-page":"E87","DOI":"10.1097\/PAS.0000000000001497","volume":"44","author":"GJLH Van Leenders","year":"2020","unstructured":"Van Leenders, G. J. L. H. et al. The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am. J. Surg. Pathol. 44, E87\u2013E99 https:\/\/doi.org\/10.1097\/PAS.0000000000001497 (2020).","journal-title":"Am. J. Surg. Pathol."},{"key":"1189_CR7","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.eururo.2020.11.021","volume":"79","author":"NK Jairath","year":"2021","unstructured":"Jairath, N. K. et al. A systematic review of the evidence for the Decipher genomic classifier in prostate cancer. Eur. Urol. 79, 374\u2013383, https:\/\/doi.org\/10.1016\/j.eururo.2020.11.021 (2021).","journal-title":"Eur. Urol."},{"key":"1189_CR8","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/J.EJCA.2014.03.009","volume":"50","author":"D Trudel","year":"2014","unstructured":"Trudel, D. et al. Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort. Eur. J. Cancer 50, 1610\u20131616 https:\/\/doi.org\/10.1016\/J.EJCA.2014.03.009 (2014).","journal-title":"Eur. J. Cancer"},{"key":"1189_CR9","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/14737140.2018.1469406","volume":"18","author":"R Montironi","year":"2018","unstructured":"Montironi, R. et al. Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma. Expert Rev. Anticancer. Ther. 18, 685\u2013693 https:\/\/doi.org\/10.1080\/14737140.2018.1469406 (2018).","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"1189_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/MODPATHOL.2014.116","volume":"28","author":"CF Kweldam","year":"2015","unstructured":"Kweldam, C. F. et al. Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer. Mod. Pathol. 28, 457\u2013464 https:\/\/doi.org\/10.1038\/MODPATHOL.2014.116 (2015).","journal-title":"Mod. Pathol."},{"key":"1189_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3976-z","author":"R B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher, R. et al. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. BMC Cancer https:\/\/doi.org\/10.1186\/s12885-017-3976-z (2018).","journal-title":"BMC Cancer"},{"key":"1189_CR12","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/J.EJCA.2012.02.003","volume":"48","author":"T Van Der Kwast","year":"2012","unstructured":"Van Der Kwast, T. et al. Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy. Eur. J. Cancer 48, 1318\u20131325 https:\/\/doi.org\/10.1016\/J.EJCA.2012.02.003 (2012).","journal-title":"Eur. J. Cancer"},{"key":"1189_CR13","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/J.UROLOGY.2017.03.030","volume":"105","author":"BF Dinerman","year":"2017","unstructured":"Dinerman, B. F., Bernstein, A. N., Khani, F. & Hu, J. C. Intraductal carcinoma of the prostate: a risk for rapid recurrence. Urology 105, e1\u2013e2 https:\/\/doi.org\/10.1016\/J.UROLOGY.2017.03.030 (2017).","journal-title":"Urology"},{"key":"1189_CR14","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/PROS.22579","volume":"73","author":"H Bonkhoff","year":"2013","unstructured":"Bonkhoff, H. et al. Intraductal carcinoma of the prostate: precursor or aggressive phenotype of prostate cancer? Prostate 73, 442\u2013448 https:\/\/doi.org\/10.1002\/PROS.22579 (2013).","journal-title":"Prostate"},{"key":"1189_CR15","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1309\/AJCPZ7WBU9YXSJPE","volume":"136","author":"KA Iczkowski","year":"2011","unstructured":"Iczkowski, K. A. et al. Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome. Am. J. Clin. Pathol. 136, 98\u2013107 https:\/\/doi.org\/10.1309\/AJCPZ7WBU9YXSJPE (2011).","journal-title":"Am. J. Clin. Pathol."},{"key":"1189_CR16","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.euo.2025.05.001","volume":"8","author":"Marra","year":"2025","unstructured":"Marra et al. Assessment of the reporting and incidence of prostate cancer unconventional histologies in tertiary referral institutions: an under-reported but exploding phenomenon? Eur. Urol. Oncol. 8, 875\u2013878 https:\/\/doi.org\/10.1016\/j.euo.2025.05.001 (2025).","journal-title":"Eur. Urol. Oncol."},{"key":"1189_CR17","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.5858\/2007-131-1103-APOTIH","volume":"131","author":"RJ Cohen","year":"2007","unstructured":"Cohen, R. J., Wheeler, T. M., Bonkhoff, H. & Rubin, M. A. A proposal on the identification, histologic reporting, and implications of intraductal prostatic carcinoma. Arch. Pathol. Lab. Med. 131, 1103\u20131109 https:\/\/doi.org\/10.5858\/2007-131-1103-APOTIH (2007).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"1189_CR18","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/00000478-199607000-00003","volume":"20","author":"JE McNeal","year":"1996","unstructured":"McNeal, J. E. & Yemoto, C. E. M. Spread of adenocarcinoma within prostatic ducts and acini: morphologic and clinical correlations. Am. J. Surg. Pathol. 20, 802\u2013814 https:\/\/doi.org\/10.1097\/00000478-199607000-00003 (1996).","journal-title":"Am. J. Surg. Pathol."},{"key":"1189_CR19","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/IJU.12657","volume":"22","author":"T Tsuzuki","year":"2015","unstructured":"Tsuzuki, T. Intraductal carcinoma of the prostate: a comprehensive and updated review. Int. J. Urol. 22, 140\u2013145 https:\/\/doi.org\/10.1111\/IJU.12657 (2015).","journal-title":"Int. J. Urol."},{"key":"1189_CR20","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/PAS.0000000000001104","volume":"42","author":"SW Fine","year":"2018","unstructured":"Fine, S. W. et al. Comedonecrosis revisited: strong association with intraductal carcinoma of the prostate. Am. J. Surg. Pathol. 42, 1036\u20131041 https:\/\/doi.org\/10.1097\/PAS.0000000000001104 (2018).","journal-title":"Am. J. Surg. Pathol."},{"key":"1189_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/path.4628","volume":"238","author":"MC Haffner","year":"2016","unstructured":"Haffner, M. C. et al. Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization. J. Pathol. 238, 31\u201341 https:\/\/doi.org\/10.1002\/path.4628 (2016).","journal-title":"J. Pathol."},{"key":"1189_CR22","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1111\/his.15414","volume":"86","author":"LL Rijstenberg","year":"2025","unstructured":"Rijstenberg, L. L. et al. Identification of intraductal-to-invasive spatial transitions in prostate cancer: proposal for a new unifying model on intraductal carcinogenesis. Histopathology 86, 1091\u20131100 https:\/\/doi.org\/10.1111\/his.15414 (2025).","journal-title":"Histopathology"},{"key":"1189_CR23","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/J.EURURO.2017.03.013","volume":"72","author":"LH Porter","year":"2017","unstructured":"Porter, L. H. et al. Systematic review links the prevalence of intraductal carcinoma of the prostate to prostate cancer risk categories. Eur. Urol. 72, 492\u2013495 https:\/\/doi.org\/10.1016\/J.EURURO.2017.03.013 (2017).","journal-title":"Eur. Urol."},{"key":"1189_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/S41391-024-00910-3","author":"RM Bernardino","year":"2024","unstructured":"Bernardino, R. M. et al. Undetected cribriform and intraductal prostate cancer at biopsy is associated with adverse outcomes. Prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/S41391-024-00910-3 (2024).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1189_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/J.EUF.2023.08.010","author":"RM Bernardino","year":"2023","unstructured":"Bernardino, R. M. et al. Limitations of prostate biopsy in detection of cribriform and intraductal prostate cancer. Eur. Urol. Focus https:\/\/doi.org\/10.1016\/J.EUF.2023.08.010 (2023).","journal-title":"Eur. Urol. Focus"},{"key":"1189_CR26","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/his.13747","volume":"74","author":"M Masoomian","year":"2019","unstructured":"Masoomian, M. et al. Concordance of biopsy and prostatectomy diagnosis of intraductal and cribriform carcinoma in a prospectively collected data set. Histopathology 74, 474\u2013482 https:\/\/doi.org\/10.1111\/his.13747 (2019).","journal-title":"Histopathology"},{"key":"1189_CR27","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/his.13893","volume":"75","author":"E Hollemans","year":"2019","unstructured":"Hollemans, E. et al. Concordance of cribriform architecture in matched prostate cancer biopsy and radical prostatectomy specimens. Histopathology 75, 338\u2013345 https:\/\/doi.org\/10.1111\/his.13893 (2019).","journal-title":"Histopathology"},{"key":"1189_CR28","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/HIS.14867","volume":"82","author":"L Egevad","year":"2023","unstructured":"Egevad, L. et al. Interobserver reproducibility of cribriform cancer in prostate needle biopsies and validation of International Society of Urological Pathology criteria. Histopathology 82, 837\u2013845 https:\/\/doi.org\/10.1111\/HIS.14867 (2023).","journal-title":"Histopathology"},{"key":"1189_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/his.70046","volume":"88","author":"RB Shah","year":"2026","unstructured":"Shah, R. B. et al. The Genitourinary Pathology Society and International Society of Urological Pathology joint expert consultation recommendations on intraductal carcinoma of the prostate. Histopathology 88, 8\u201323 https:\/\/doi.org\/10.1111\/his.70046 (2026).","journal-title":"Histopathology"},{"key":"1189_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33780-1","author":"HY Wong","year":"2022","unstructured":"Wong, H. Y. et al. Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease. Nat. Commun. https:\/\/doi.org\/10.1038\/s41467-022-33780-1 (2022).","journal-title":"Nat. Commun."},{"key":"1189_CR31","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.eururo.2017.04.034","volume":"72","author":"MLK Chua","year":"2017","unstructured":"Chua, M. L. K. et al. A prostate cancer \u201cnimbosus\u201d: genomic instability and SChLAP1 dysregulation underpin aggression of intraductal and cribriform subpathologies. Eur. Urol. 72, 665\u2013674 https:\/\/doi.org\/10.1016\/j.eururo.2017.04.034 (2017).","journal-title":"Eur. Urol."},{"key":"1189_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.eururo.2018.12.036","volume":"76","author":"KE Houlahan","year":"2019","unstructured":"Houlahan, K. E. et al. Molecular hallmarks of multiparametric MRI visibility in prostate cancer. Eur. Urol. 76, 18\u201323 https:\/\/doi.org\/10.1016\/j.eururo.2018.12.036 (2019).","journal-title":"Eur. Urol."},{"key":"1189_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-024-75272-W","author":"R Bernardino","year":"2024","unstructured":"Bernardino, R. et al. Profiling of urinary extracellular vesicle protein signatures from patients with cribriform and intraductal prostate carcinoma in a cross-sectional study. Sci. Rep. https:\/\/doi.org\/10.1038\/S41598-024-75272-W (2024).","journal-title":"Sci. Rep."},{"key":"1189_CR34","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.eururo.2014.08.007","volume":"67","author":"GP Risbridger","year":"2015","unstructured":"Risbridger, G. P. et al. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. Eur. Urol. 67, 496\u2013503 https:\/\/doi.org\/10.1016\/j.eururo.2014.08.007 (2015).","journal-title":"Eur. Urol."},{"key":"1189_CR35","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejca.2021.01.027","volume":"147","author":"R Lozano","year":"2021","unstructured":"Lozano, R. et al. Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. Eur. J. Cancer 147, 74\u201383 https:\/\/doi.org\/10.1016\/j.ejca.2021.01.027 (2021).","journal-title":"Eur. J. Cancer"},{"key":"1189_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100489","author":"S Prendeville","year":"2024","unstructured":"Prendeville, S. et al. Somatic tumor testing in prostate cancer: experience of a tertiary care center including pathologist-driven reflex testing of localized tumors at diagnosis. Mod. Pathol. https:\/\/doi.org\/10.1016\/j.modpat.2024.100489 (2024).","journal-title":"Mod. Pathol."},{"key":"1189_CR37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi, H. A. et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 386, 24\u201334 https:\/\/doi.org\/10.1056\/NEJMoa2109970 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1189_CR38","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-024-02965-0","volume":"30","author":"M Schuler","year":"2024","unstructured":"Schuler, M. et al. Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial. Nat. Med. 30, 1602\u20131611 https:\/\/doi.org\/10.1038\/s41591-024-02965-0 (2024).","journal-title":"Nat. Med."},{"key":"1189_CR39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/PATH.5283","volume":"249","author":"F Khani","year":"2019","unstructured":"Khani, F. et al. Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations. J. Pathol. 249, 79\u201389 https:\/\/doi.org\/10.1002\/PATH.5283 (2019).","journal-title":"J. Pathol."},{"key":"1189_CR40","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1097\/PAS.0000000000001728","volume":"45","author":"TH Van Der Kwast","year":"2021","unstructured":"Van Der Kwast, T. H. et al. ISUP consensus definition of cribriform pattern prostate cancer. Am. J. Surg. Pathol. 45, 1118\u20131126 https:\/\/doi.org\/10.1097\/PAS.0000000000001728 (2021).","journal-title":"Am. J. Surg. Pathol."},{"key":"1189_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2021.151733","volume":"52","author":"KA Iczkowski","year":"2021","unstructured":"Iczkowski, K. A. et al. Cribriform prostate cancer: morphologic criteria enabling a diagnosis, based on survey of experts. Ann. Diagn. Pathol. 52, 151733 https:\/\/doi.org\/10.1016\/j.anndiagpath.2021.151733 (2021).","journal-title":"Ann. Diagn. Pathol."},{"key":"1189_CR42","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/modpathol.2012.201","volume":"26","author":"TL Lotan","year":"2013","unstructured":"Lotan, T. L. et al. Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia. Mod. Pathol. 26, 587\u2013603 https:\/\/doi.org\/10.1038\/modpathol.2012.201 (2013).","journal-title":"Mod. Pathol."},{"key":"1189_CR43","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/PAS.0000000000000348","volume":"39","author":"CL Morais","year":"2015","unstructured":"Morais, C. L. et al. Utility of PTEN and ERG immunostaining for distinguishing high-grade PIN from intraductal carcinoma of the prostate on needle biopsy. Am. J. Surg. Pathol. 39, 169\u2013178 https:\/\/doi.org\/10.1097\/PAS.0000000000000348 (2015).","journal-title":"Am. J. Surg. Pathol."},{"key":"1189_CR44","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1177\/1066896916668639","volume":"24","author":"AM Acosta","year":"2016","unstructured":"Acosta, A. M., Sharif, A., Groth, J. V. & Kajdacsy-Balla, A. Ductal spread versus high-grade prostatic intraepithelial neoplasia: a diagnostic pitfall. Int. J. Surg. Pathol. 24, 718\u2013719 https:\/\/doi.org\/10.1177\/1066896916668639 (2016).","journal-title":"Int. J. Surg. Pathol."},{"key":"1189_CR45","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.eururo.2006.07.048","volume":"50","author":"R Montironi","year":"2006","unstructured":"Montironi, R. et al. Atypical foci suspicious but not diagnostic of malignancy in prostate needle biopsies (also referred to as \u201catypical small acinar proliferation suspicious for but not diagnostic of malignancy\u201d). Eur. Urol. 50, 666\u2013674 https:\/\/doi.org\/10.1016\/j.eururo.2006.07.048 (2006).","journal-title":"Eur. Urol."},{"key":"1189_CR46","doi-asserted-by":"publisher","first-page":"461","DOI":"10.5858\/ARPA.2020-0015-RA","volume":"145","author":"JI Epstein","year":"2021","unstructured":"Epstein, J. I. et al. The 2019 Genitourinary Pathology Society (GUPS) white paper on contemporary grading of prostate cancer. Arch. Pathol. Lab. Med. 145, 461\u2013493 https:\/\/doi.org\/10.5858\/ARPA.2020-0015-RA (2021).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"1189_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/J.EURURO.2023.03.014","author":"G Marra","year":"2023","unstructured":"Marra, G. et al. Impact of epithelial histological types, subtypes, and growth patterns on oncological outcomes for patients with nonmetastatic prostate cancer treated with curative intent: a systematic review. Eur. Urol. https:\/\/doi.org\/10.1016\/J.EURURO.2023.03.014 (2023).","journal-title":"Eur. Urol."},{"key":"1189_CR48","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/S41379-022-01009-7","volume":"35","author":"E Chan","year":"2022","unstructured":"Chan, E. et al. Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for \u201clarge\u201d cribriform prostatic adenocarcinoma. Mod. Pathol. 35, 1092\u20131100 https:\/\/doi.org\/10.1038\/S41379-022-01009-7 (2022).","journal-title":"Mod. Pathol."},{"key":"1189_CR49","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/HIS.15102","volume":"84","author":"NY Greenland","year":"2024","unstructured":"Greenland, N. Y. et al. Large cribriform glands (>0.25\u2009mm diameter) as a predictor of adverse pathology in men with grade group 2 prostate cancer. Histopathology 84, 14\u201323 https:\/\/doi.org\/10.1111\/HIS.15102 (2024).","journal-title":"Histopathology"},{"key":"1189_CR50","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/HIS.14658","volume":"80","author":"LL Rijstenberg","year":"2022","unstructured":"Rijstenberg, L. L. et al. Large and small cribriform architecture have similar adverse clinical outcome on prostate cancer biopsies. Histopathology 80, 1041 https:\/\/doi.org\/10.1111\/HIS.14658 (2022).","journal-title":"Histopathology"},{"key":"1189_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/J.PATHOL.2024.08.012","author":"Y Wang","year":"2024","unstructured":"Wang, Y., Teramoto, Y. & Miyamoto, H. Cribriform intraductal carcinoma of the prostate may be more aggressive than cribriform conventional\/acinar prostatic adenocarcinoma. Pathology https:\/\/doi.org\/10.1016\/J.PATHOL.2024.08.012 (2024).","journal-title":"Pathology"},{"key":"1189_CR52","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/JU.0000000000001290","volume":"204","author":"N Miura","year":"2020","unstructured":"Miura, N. et al. The prognostic impact of intraductal carcinoma of the prostate: a systematic review and meta-analysis. J. Urol. 204, 909\u2013917 https:\/\/doi.org\/10.1097\/JU.0000000000001290 (2020).","journal-title":"J. Urol."},{"key":"1189_CR53","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/S41379-018-0157-9","volume":"32","author":"E Hollemans","year":"2019","unstructured":"Hollemans, E. et al. Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis. Mod. Pathol. 32, 139\u2013146 https:\/\/doi.org\/10.1038\/S41379-018-0157-9 (2019).","journal-title":"Mod. Pathol."},{"key":"1189_CR54","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.humpath.2021.09.005","volume":"118","author":"Z Chen","year":"2021","unstructured":"Chen, Z. et al. Prognostic value of cribriform size, percentage, and intraductal carcinoma in Gleason score 7 prostate cancer with cribriform Gleason pattern 4. Hum. Pathol. 118, 18\u201329 https:\/\/doi.org\/10.1016\/j.humpath.2021.09.005 (2021).","journal-title":"Hum. Pathol."},{"key":"1189_CR55","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/J.HUMPATH.2023.01.008","volume":"135","author":"Y Okubo","year":"2023","unstructured":"Okubo, Y. et al. Cribriform pattern and intraductal carcinoma of the prostate can have a clinicopathological impact, regardless of their percentage and\/or number of cores. Hum. Pathol. 135, 99\u2013107 https:\/\/doi.org\/10.1016\/J.HUMPATH.2023.01.008 (2023).","journal-title":"Hum. Pathol."},{"key":"1189_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-026-01143-2","author":"F Ditonno","year":"2026","unstructured":"Ditonno, F. et al. Prognostic value of cribriform pattern and intraductal carcinoma of the prostate after radical prostatectomy: a systematic review and meta-analysis using contemporary consensus recommendations. Prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/s41391-026-01143-2 (2026).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1189_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS222413605","author":"RMM Bernardino","year":"2021","unstructured":"Bernardino, R. M. M. et al. Extracellular vesicle proteome in prostate cancer: a comparative analysis of mass spectrometry studies. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/IJMS222413605 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1189_CR58","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/S00345-024-05369-4","volume":"42","author":"RM Bernardino","year":"2024","unstructured":"Bernardino, R. M. et al. Can the free\/total PSA ratio predict undetected intraductal carcinoma and cribriform pattern at biopsy? World J. Urol. 42, 651 https:\/\/doi.org\/10.1007\/S00345-024-05369-4 (2024).","journal-title":"World J. Urol."},{"key":"1189_CR59","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"Bono","year":"2020","unstructured":"Bono et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 382, 2091\u20132102 https:\/\/doi.org\/10.1056\/NEJMoa1911440 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1189_CR60","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.annonc.2025.10.004","volume":"37","author":"K Fizazi","year":"2026","unstructured":"Fizazi, K. et al. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Ann. Oncol. 37, 53\u201368 https:\/\/doi.org\/10.1016\/j.annonc.2025.10.004 (2026).","journal-title":"Ann. Oncol."},{"key":"1189_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-19283-1","volume":"15","author":"Z Han","year":"2025","unstructured":"Han, Z. et al. The expression of prostate-specific membrane antigen in intraductal carcinoma of the prostate. Sci. Rep. 15, 35326 https:\/\/doi.org\/10.1038\/s41598-025-19283-1 (2025).","journal-title":"Sci. Rep."},{"key":"1189_CR62","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"Sartor","year":"2021","unstructured":"Sartor et al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091\u20131103 https:\/\/doi.org\/10.1056\/NEJMoa2107322 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1189_CR63","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.eururo.2022.09.004","volume":"83","author":"C Guo","year":"2023","unstructured":"Guo, C. et al. B7-H3 as a therapeutic target in advanced prostate cancer. Eur. Urol. 83, 224\u2013238 https:\/\/doi.org\/10.1016\/j.eururo.2022.09.004 (2023).","journal-title":"Eur. Urol."},{"key":"1189_CR64","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70238","volume":"132","author":"H Dudipala","year":"2026","unstructured":"Dudipala, H. et al. Molecular alteration profiles characterize intraductal carcinoma of the prostate. Cancer 132, e70238 https:\/\/doi.org\/10.1002\/cncr.70238 (2026).","journal-title":"Cancer"},{"key":"1189_CR65","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/JU.0000000000000526","volume":"203","author":"KJ Ericson","year":"2020","unstructured":"Ericson, K. J. et al. Diagnostic accuracy of prostate biopsy for detecting cribriform gleason pattern 4 carcinoma and intraductal carcinoma in paired radical prostatectomy specimens: implications for active surveillance. J. Urol. 203, 311\u2013319 https:\/\/doi.org\/10.1097\/JU.0000000000000526 (2020).","journal-title":"J. Urol."},{"key":"1189_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/S41391-022-00641-3","author":"R Hogenhout","year":"2023","unstructured":"Hogenhout, R., Remmers, S., van Leenders, G. J. L. H. & Roobol, M. J. The transition from transrectal to transperineal prostate biopsy without antibiotic prophylaxis: cancer detection rates and complication rates. Prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/S41391-022-00641-3 (2023).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1189_CR67","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1038\/S41379-022-01111-W","volume":"35","author":"Y Yu","year":"2022","unstructured":"Yu, Y. et al. Impact of cribriform pattern 4 and intraductal prostatic carcinoma on national comprehensive cancer network (NCCN) and cancer of prostate risk assessment (CAPRA) patient stratification. Mod. Pathol. 35, 1695\u20131701 https:\/\/doi.org\/10.1038\/S41379-022-01111-W (2022).","journal-title":"Mod. Pathol."},{"key":"1189_CR68","doi-asserted-by":"publisher","DOI":"10.1002\/CAM4.7086","author":"K Shimodaira","year":"2024","unstructured":"Shimodaira, K. et al. Significance of the cribriform morphology area ratio for biochemical recurrence in Gleason score 4 + 4 prostate cancer patients following robot-assisted radical prostatectomy. Cancer Med. https:\/\/doi.org\/10.1002\/CAM4.7086 (2024).","journal-title":"Cancer Med."},{"key":"1189_CR69","first-page":"3990","volume":"11","author":"RB Shah","year":"2021","unstructured":"Shah, R. B. et al. Diagnosis of \u201ccribriform\u201d prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations. Am. J. Cancer Res. 11, 3990 (2021).","journal-title":"Am. J. Cancer Res."},{"key":"1189_CR70","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/his.12976","volume":"69","author":"CF Kweldam","year":"2016","unstructured":"Kweldam, C. F. et al. Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. Histopathology 69, 441\u2013449 https:\/\/doi.org\/10.1111\/his.12976 (2016).","journal-title":"Histopathology"},{"key":"1189_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-025-01106-7","author":"RM Bernardino","year":"2025","unstructured":"Bernardino, R. M. et al. Atypical intraductal proliferation in prostate biopsy \u2014 a diagnostic grey zone with clinical implications. Nat. Rev. Urol. https:\/\/doi.org\/10.1038\/s41585-025-01106-7 (2025).","journal-title":"Nat. Rev. Urol."},{"key":"1189_CR72","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/HIS.13878","volume":"75","author":"RB Shah","year":"2019","unstructured":"Shah, R. B. et al. Atypical intraductal proliferation detected in prostate needle biopsy is a marker of unsampled intraductal carcinoma and other adverse pathological features: a prospective clinicopathological study of 62 cases with emphasis on pathological outcomes. Histopathology 75, 346\u2013353 https:\/\/doi.org\/10.1111\/HIS.13878 (2019).","journal-title":"Histopathology"},{"key":"1189_CR73","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1007\/S00259-019-04320-9","volume":"46","author":"J Gao","year":"2019","unstructured":"Gao, J. et al. Diagnostic performance of 68Ga-PSMA PET\/CT for identification of aggressive cribriform morphology in prostate cancer with whole-mount sections. Eur. J. Nucl. Med. Mol. Imaging 46, 1531\u20131541 https:\/\/doi.org\/10.1007\/S00259-019-04320-9 (2019).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1189_CR74","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.2967\/jnumed.124.268443","volume":"65","author":"I Sonni","year":"2024","unstructured":"Sonni, I. et al. Clinical, pathologic, and imaging variables associated with prostate cancer detection by PSMA PET\/CT and multiparametric MRI. J. Nucl. Med. 65, 1923\u20131931 https:\/\/doi.org\/10.2967\/jnumed.124.268443 (2024).","journal-title":"J. Nucl. Med."},{"key":"1189_CR75","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.3390\/cancers15061716","volume":"15","author":"L Vetrone","year":"2023","unstructured":"Vetrone, L. et al. Histology and PSMA expression on immunohistochemistry in high-risk prostate cancer patients: comparison with 68Ga-PSMA PET\/CT features in primary staging. Cancers 15, 1716 https:\/\/doi.org\/10.3390\/cancers15061716 (2023).","journal-title":"Cancers"},{"key":"1189_CR76","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/JU.0000000000004734","volume":"214","author":"DC Chen","year":"2025","unstructured":"Chen, D. C. et al. The blind spot of prostate-specific membrane antigen positron emission tomography staging? Intraductal carcinoma of the prostate is overrepresented in patients with no uptake pattern on prostate-specific membrane antigen positron emission tomography and high-grade prostate cancer. J. Urol. 214, 582\u2013590 https:\/\/doi.org\/10.1097\/JU.0000000000004734 (2025).","journal-title":"J. Urol."},{"key":"1189_CR77","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/s12149-023-01864-7","volume":"37","author":"LA Guner","year":"2023","unstructured":"Guner, L. A. et al. Enhancing PSMA PET\/CT imaging of prostate cancer: investigating the impact of multiple time point evaluation, diuretic administration, cribriform pattern, and intraductal carcinoma. Ann. Nucl. Med. 37, 618\u2013628 https:\/\/doi.org\/10.1007\/s12149-023-01864-7 (2023).","journal-title":"Ann. Nucl. Med."},{"key":"1189_CR78","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.euo.2022.04.006","volume":"5","author":"T Kawada","year":"2022","unstructured":"Kawada, T. et al. Diagnostic performance of prostate-specific membrane antigen positron emission tomography \u2014 targeted biopsy for detection of clinically significant prostate cancer: a systematic review and meta-analysis. Eur. Urol. Oncol. 5, 390\u2013400 https:\/\/doi.org\/10.1016\/j.euo.2022.04.006 (2022).","journal-title":"Eur. Urol. Oncol."},{"key":"1189_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2025.102348","volume":"23","author":"L Bianchi","year":"2025","unstructured":"Bianchi, L. et al. PSMA-targeted biopsy with fusion guidance for detecting clinically significant prostate cancer in men with negative MRI-feasibility and diagnostic performance of a pilot single-center prospective study. Clin. Genitourin. Cancer 23, 102348 https:\/\/doi.org\/10.1016\/j.clgc.2025.102348 (2025).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1189_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/J.EUF.2023.05.005","author":"R Bernardino","year":"2023","unstructured":"Bernardino, R. et al. Lymphotropic pattern of prostate-specific membrane antigen-detected metastases among biochemically recurrent radical prostatectomy patients with cribriform disease. Eur. Urol. Focus https:\/\/doi.org\/10.1016\/J.EUF.2023.05.005 (2023).","journal-title":"Eur. Urol. Focus"},{"key":"1189_CR81","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.euros.2025.09.015","volume":"82","author":"RM Bernardino","year":"2025","unstructured":"Bernardino, R. M. et al. Intraductal carcinoma predicts poor response to neoadjuvant therapy in high-risk prostate cancer: a retrospective analysis of a prospective trial. Eur. Urol. Open Sci. 82, 52\u201358 https:\/\/doi.org\/10.1016\/j.euros.2025.09.015 (2025).","journal-title":"Eur. Urol. Open Sci."},{"key":"1189_CR82","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/bco2.60","volume":"2","author":"N Ranasinha","year":"2021","unstructured":"Ranasinha, N. et al. Ductal adenocarcinoma of the prostate: a systematic review and meta-analysis of incidence, presentation, prognosis, and management. BJUI Compass 2, 13\u201323 https:\/\/doi.org\/10.1002\/bco2.60 (2021).","journal-title":"BJUI Compass"},{"key":"1189_CR83","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003850","author":"R Bernardino","year":"2024","unstructured":"Bernardino, R. et al. Intraductal prostate cancer affinity for lymphatic-predominant metastases through 18F-DCFPyL\u2013prostate-specific membrane antigen\u2013positron emission tomography\/CT scans in pretreatment prostate cancer patients. J. Urol. https:\/\/doi.org\/10.1097\/JU.0000000000003850 (2024).","journal-title":"J. Urol."},{"key":"1189_CR84","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/BCO2.151","volume":"3","author":"D Bolton","year":"2022","unstructured":"Bolton, D. et al. Cribriform pattern disease over-represented in pelvic lymph node metastases identified on 68GA PSMA-PET\/CT. BJUI Compass 3, 371\u2013376 https:\/\/doi.org\/10.1002\/BCO2.151 (2022).","journal-title":"BJUI Compass"},{"key":"1189_CR85","doi-asserted-by":"publisher","DOI":"10.1111\/BJU.16162","author":"R Bernardino","year":"2023","unstructured":"Bernardino, R. et al. Increasing trend of utilising active surveillance for Gleason score 7 (3 + 4) prostate cancer. BJU Int. https:\/\/doi.org\/10.1111\/BJU.16162 (2023).","journal-title":"BJU Int."},{"key":"1189_CR86","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford, P. et al. EAU\u2013EANM\u2013ESTRO\u2013ESUR\u2013ISUP\u2013SIOG guidelines on prostate cancer \u2014 2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur. Urol. 86, 148\u2013163 https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027 (2024).","journal-title":"Eur. Urol."},{"key":"1189_CR87","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2019.07.051","volume":"77","author":"GJLH Van Leenders","year":"2020","unstructured":"Van Leenders, G. J. L. H. et al. Improved prostate cancer biopsy grading by incorporation of invasive cribriform and intraductal carcinoma in the 2014 grade groups. Eur. Urol. 77, 191\u2013198 https:\/\/doi.org\/10.1016\/j.eururo.2019.07.051 (2020).","journal-title":"Eur. Urol."},{"key":"1189_CR88","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/his.15231","volume":"85","author":"JK Nguyen","year":"2024","unstructured":"Nguyen, J. K. et al. Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage. Histopathology 85, 598\u2013613 https:\/\/doi.org\/10.1111\/his.15231 (2024).","journal-title":"Histopathology"},{"key":"1189_CR89","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1001\/jamaoncol.2025.4125","volume":"11","author":"N Sushentsev","year":"2025","unstructured":"Sushentsev, N. et al. Active monitoring, surgery, and radiotherapy for cribriform-positive and cribriform-negative prostate cancer: a secondary analysis of the PROTECT randomized clinical trial. JAMA Oncol. 11, 1512\u20131517 https:\/\/doi.org\/10.1001\/jamaoncol.2025.4125 (2025).","journal-title":"JAMA Oncol."},{"key":"1189_CR90","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.euf.2025.11.021","volume":"12","author":"R Bernardino","year":"2025","unstructured":"Bernardino, R., Le Guev\u00e9lou, J., Autorino, R., Gandaglia, G. & Marra, G. (Young Academic Urologists Prostate Group). Re: Nikita Sushentsev, Anne Y. Warren, Richard Colling, et al. Active monitoring, surgery, and radiotherapy for cribriform-positive and cribriform-negative prostate cancer: a secondary analysis of the protect randomized clinical trial. Eur. Urol. Focus. 12, 610\u2013611, https:\/\/doi.org\/10.1016\/j.euf.2025.11.021 (2025).","journal-title":"Eur. Urol. Focus."},{"key":"1189_CR91","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/S00330-025-11603-3","volume":"36","author":"F Carletti","year":"2025","unstructured":"Carletti, F. et al. Diagnostic accuracy of multiparametric MRI for detecting unconventional prostate cancer histology: a systematic review and meta-analysis. Eur. Radiol. 36, 17\u201329 https:\/\/doi.org\/10.1007\/S00330-025-11603-3 (2025).","journal-title":"Eur. Radiol."},{"key":"1189_CR92","doi-asserted-by":"publisher","first-page":"38.e1","DOI":"10.1016\/J.UROLONC.2019.09.029","volume":"38","author":"P Mithal","year":"2020","unstructured":"Mithal, P. et al. Cribriform pattern and perineural invasion on MR\/US fusion biopsy predict failure of selection criteria for prostatic hemigland ablation. Urol. Oncol. 38, 38.e1\u201338.e8 https:\/\/doi.org\/10.1016\/J.UROLONC.2019.09.029 (2020).","journal-title":"Urol. Oncol."},{"key":"1189_CR93","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/bju.70277","volume":"138","author":"J Carll","year":"2026","unstructured":"Carll, J. et al. Guideline of guidelines: pelvic lymph node dissection at time of radical prostatectomy. BJU Int. 138, 208\u2013218 https:\/\/doi.org\/10.1111\/bju.70277 (2026).","journal-title":"BJU Int."},{"key":"1189_CR94","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.eururo.2011.10.044","volume":"61","author":"A Briganti","year":"2012","unstructured":"Briganti, A. et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur. Urol. 61, 480\u2013487 https:\/\/doi.org\/10.1016\/j.eururo.2011.10.044 (2012).","journal-title":"Eur. Urol."},{"key":"1189_CR95","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.eururo.2018.10.012","volume":"75","author":"G Gandaglia","year":"2019","unstructured":"Gandaglia, G. et al. A novel nomogram to identify candidates for extended pelvic lymph node dissection among patients with clinically localized prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies. Eur. Urol. 75, 506\u2013514 https:\/\/doi.org\/10.1016\/j.eururo.2018.10.012 (2019).","journal-title":"Eur. Urol."},{"key":"1189_CR96","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.urology.2022.04.043","volume":"168","author":"HA de Barros","year":"2022","unstructured":"de Barros, H. A. et al. Predictive value of cribriform and intraductal carcinoma for the nomogram-based selection of prostate cancer patients for pelvic lymph node dissection. Urology 168, 156\u2013164 https:\/\/doi.org\/10.1016\/j.urology.2022.04.043 (2022).","journal-title":"Urology"},{"key":"1189_CR97","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/his.13938","volume":"75","author":"MR Downes","year":"2019","unstructured":"Downes, M. R., Xu, B. & van der Kwast, T. H. Gleason grade patterns in nodal metastasis and corresponding prostatectomy specimens: impact on patient outcome. Histopathology 75, 715\u2013722 https:\/\/doi.org\/10.1111\/his.13938 (2019).","journal-title":"Histopathology"},{"key":"1189_CR98","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/J.EJCA.2020.09.016","volume":"148","author":"MR Downes","year":"2021","unstructured":"Downes, M. R., Xu, B. & van der Kwast, T. H. Cribriform architecture prostatic adenocarcinoma in needle biopsies is a strong independent predictor for lymph node metastases in radical prostatectomy. Eur. J. Cancer 148, 432\u2013439 https:\/\/doi.org\/10.1016\/J.EJCA.2020.09.016 (2021).","journal-title":"Eur. J. Cancer"},{"key":"1189_CR99","doi-asserted-by":"publisher","first-page":"67.e9","DOI":"10.1016\/J.UROLONC.2023.11.018","volume":"42","author":"B Wang","year":"2024","unstructured":"Wang, B. et al. The presence of intraductal carcinoma of prostate is a risk factor for poor pathologic response in men with high-risk prostate cancer receiving neoadjuvant therapy. Urol. Oncol. Semin. Orig. Invest. 42, 67.e9\u201367.e15 https:\/\/doi.org\/10.1016\/J.UROLONC.2023.11.018 (2024).","journal-title":"Urol. Oncol. Semin. Orig. Invest."},{"key":"1189_CR100","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/BJU.14043","volume":"121","author":"LH Porter","year":"2018","unstructured":"Porter, L. H. et al. Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cells. BJU Int. 121, 971\u2013978 https:\/\/doi.org\/10.1111\/BJU.14043 (2018).","journal-title":"BJU Int."},{"key":"1189_CR101","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.euros.2026.03.007","volume":"91","author":"RM Bernardino","year":"2026","unstructured":"Bernardino, R. M. et al. Reply to Dr. Zhang\u2019s Letter to the Editor re: R.M. Bernardino, L.B. Yin, K. Lajkosz, et al. Intraductal carcinoma predicts poor response to neoadjuvant therapy in high-risk prostate cancer: a retrospective analysis of a prospective trial. Eur. Urol. Open. Sci. 91, 93\u201394 https:\/\/doi.org\/10.1016\/j.euros.2026.03.007 (2026).","journal-title":"Eur. Urol. Open. Sci."},{"key":"1189_CR102","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1097\/JU.0000000000001632","volume":"205","author":"RR McKay","year":"2021","unstructured":"McKay, R. R. et al. Outcomes of post-neoadjuvant intense hormone therapy and surgery for high risk localized prostate cancer: results of a pooled analysis of contemporary clinical trials. J. Urol. 205, 1689\u20131697 https:\/\/doi.org\/10.1097\/JU.0000000000001632 (2021).","journal-title":"J. Urol."},{"key":"1189_CR103","doi-asserted-by":"publisher","first-page":"TPS285","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS285","volume":"40","author":"AS Kibel","year":"2022","unstructured":"Kibel, A. S. et al. PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients (pts) with localized or locally advanced high-risk prostate cancer (PC). J. Clin. Oncol. 40, TPS285 https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.TPS285 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1189_CR104","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.euo.2023.09.020","volume":"7","author":"G Calleris","year":"2024","unstructured":"Calleris, G. et al. Surgery with or without darolutamide in high-risk and\/or locally advanced prostate cancer: the SUGAR (CCAFU-PR2) phase 2 trial rationale and protocol. Eur. Urol. Oncol. 7, 494\u2013500 https:\/\/doi.org\/10.1016\/j.euo.2023.09.020 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"1189_CR105","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1200\/JCO.2025.43.5_SUPPL.417","volume":"43","author":"R Bernardino","year":"2025","unstructured":"Bernardino, R. et al. Genomic alterations in intraductal prostate cancer: insights from the genomic umbrella neoadjuvant study (GUNS) in high-risk localized disease. J. Clin. Oncol. 43, 417\u2013417 https:\/\/doi.org\/10.1200\/JCO.2025.43.5_SUPPL.417 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1189_CR106","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/gcc.20560","volume":"47","author":"O Bettendorf","year":"2008","unstructured":"Bettendorf, O. et al. Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate. Genes. Chromosomes Cancer 47, 565\u2013572 https:\/\/doi.org\/10.1002\/gcc.20560 (2008).","journal-title":"Genes. Chromosomes Cancer"},{"key":"1189_CR107","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/J.EURURO.2021.03.009","volume":"80","author":"S Wilkinson","year":"2021","unstructured":"Wilkinson, S. et al. Nascent prostate cancer heterogeneity drives evolution and resistance to intense hormonal therapy. Eur. Urol. 80, 746\u2013757 https:\/\/doi.org\/10.1016\/J.EURURO.2021.03.009 (2021).","journal-title":"Eur. Urol."},{"key":"1189_CR108","doi-asserted-by":"publisher","first-page":"4716","DOI":"10.1158\/0008-5472.CAN-18-0610","volume":"78","author":"AG Sowalsky","year":"2018","unstructured":"Sowalsky, A. G. et al. Neoadjuvant-intensive androgen deprivation therapy selects for prostate tumor foci with diverse subclonal oncogenic alterations. Cancer Res. 78, 4716\u20134730 https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0610 (2018).","journal-title":"Cancer Res."},{"key":"1189_CR109","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/PROS.23942","volume":"80","author":"M Kato","year":"2020","unstructured":"Kato, M. et al. Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients. Prostate 80, 284\u2013290 https:\/\/doi.org\/10.1002\/PROS.23942 (2020).","journal-title":"Prostate"},{"key":"1189_CR110","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1038\/modpathol.2017.158","volume":"31","author":"AJ Evans","year":"2018","unstructured":"Evans, A. J. Treatment effects in prostate cancer. Mod. Pathol. 31, S110\u2013S121 https:\/\/doi.org\/10.1038\/modpathol.2017.158 (2018).","journal-title":"Mod. Pathol."},{"key":"1189_CR111","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/J.EURURO.2009.10.020","volume":"57","author":"E Efstathiou","year":"2010","unstructured":"Efstathiou, E. et al. Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification. Eur. Urol. 57, 1030 https:\/\/doi.org\/10.1016\/J.EURURO.2009.10.020 (2010).","journal-title":"Eur. Urol."},{"key":"1189_CR112","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/pros.23777","volume":"79","author":"X Wang","year":"2019","unstructured":"Wang, X. et al. Differential response to neoadjuvant hormonal therapy in prostate cancer: predictive morphological parameters and molecular markers. Prostate 79, 709\u2013719 https:\/\/doi.org\/10.1002\/pros.23777 (2019).","journal-title":"Prostate"},{"key":"1189_CR113","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2485399","volume":"57","author":"K Shi","year":"2025","unstructured":"Shi, K. et al. Prognostic value of pathological sensitivity for high-risk, localized prostate cancer receiving neoadjuvant hormonal therapy combined with radical prostatectomy. Ann. Med. 57, 2485399 https:\/\/doi.org\/10.1080\/07853890.2025.2485399 (2025).","journal-title":"Ann. Med."},{"key":"1189_CR114","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1309\/AJCP8EL5FTZSOBIH","volume":"133","author":"C O\u2019Brien","year":"2010","unstructured":"O\u2019Brien, C. et al. Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer. Am. J. Clin. Pathol. 133, 654\u2013661 https:\/\/doi.org\/10.1309\/AJCP8EL5FTZSOBIH (2010).","journal-title":"Am. J. Clin. Pathol."},{"key":"1189_CR115","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/MOU.0000000000001347","volume":"36","author":"N Khalil","year":"2026","unstructured":"Khalil, N. et al. Cribriform carcinoma of the prostate, as aggressive as it sounds? A narrative review from the EAU section of endourology. Curr. Opin. Urol. 36, 72\u201378 https:\/\/doi.org\/10.1097\/MOU.0000000000001347 (2026).","journal-title":"Curr. Opin. Urol."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01189-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01189-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01189-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:01:38Z","timestamp":1791561698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01189-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":115,"alternative-id":["1189"],"URL":"https:\/\/doi.org\/10.1038\/s41585-026-01189-w","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"15 September 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}